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ABSTRACT
Convergent evidence indicates that
abnormalities in the innate immune system
may be pertinent to the pathogenesis,
phenomenology, and possible treatment of
several mental disorders. In keeping with this
view, the targeting of interleukin-6 with the
human monoclonal antibody sirukumab may
represent a possible treatment and disease
modification approach, for adults with
brain-based disorders (e.g., major depressive
disorder). A PubMed/Medline database search
was performed using the following search
terms: sirukumab; anti-IL-6; IL-6; major
depressive disorder; inflammation. A
systematic review was conducted of both
preclinical and clinical trials reporting on the
pharmacology of sirukumab or investigating the
efficacy of targeting IL-6 signaling. Overall,
sirukumab has been reported to be a safe and
well-tolerated agent, capable of modulating the
immune response in healthy populations as
well as in subjects with inflammatory disorders
(e.g., rheumatoid arthritis). Sirukumab’s effects
on cytokine networks as part of the innate
immune system provide a coherent rationale for
possible application in neuropsychiatric
disorders with possible benefits across several
domains of the biobehavioral Research Domain
Criteria matrix (e.g., general cognitive
processes, positive valence systems). Amongst
individuals with complex brain-based disorders
(e.g., mood disorders), the dimensions/domains
most likely to benefit with sirukumab are
negative valence disturbances (e.g., anxiety,
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depression, rumination), positive valence
disturbances (e.g., anhedonia) as well as
general cognitive processes. We suggest that
sirukumab represents a prototype and possibly a
proof-of-concept that agents that engage IL-6
targets have salutary effects in psychiatry.




Currently available antidepressants primarily
target monoaminergic systems via effects on
either monoamine reuptake inhibition,
receptor modulation, or monoamine oxidase
inhibition [1]. Available evidence indicates that
antidepressants are highly effective for a subset
of individuals with major depressive disorder
(MDD) and minimally effective for a larger
proportion of affected individuals [2–4]. The
foregoing therapeutic deficiency in treatment
outcomes, as well as the relatively high rates of
discontinuation (i.e., 43–61%) due to
treatment-emergent adverse events [5],
underscores the need for genuinely novel
treatments that primarily engage
non-monoaminergic molecular targets. In
addition to suboptimal
symptomatic/functional outcomes with
existing antidepressants, there is no
compelling evidence that existing therapies are
capable of disease modification in MDD.
Several non-mutually exclusive effector
systems are implicated in the pathoetiology of
MDD including, but not limited to,
dysregulation of the innate immune
inflammatory system [6–10]. The innate
immune inflammatory system provides
immediate defense against pathogens
introduced to the body (e.g., resulting from
injury or infection) and as a repair system for
damaged tissue. Notwithstanding the
evolutionary benefits of the inflammatory
response in the presence of physical threat, its
overactivity in response to everyday social
stressors is thought to result in depressive
symptomology [11]. A detailed review of the
role of inflammation in depression, including
the neurochemical mechanisms by which the
immune system affects mood and behavior, is
outlined from an evolutionary perspective
elsewhere [12]. Components of the innate
immune response include the action of several
cytokines, chemokines, cellular adhesion
molecules, and acute phase reactants. Of the
foregoing categories of inflammatory protein
systems, alteration in interleukin-6 (IL-6) levels
has been identified as one of the most
reproducible abnormalities in MDD [13].
In addition to being an intrinsic abnormality
in adults with MDD, for many individuals with
MDD, alterations in the immune inflammatory
system are a secondary phenomenon to either
the behavioral disturbances observed in
depression (e.g., sleep disturbance),
comorbidity (e.g., obesity), and/or iatrogenic
effects (e.g., weight-gain-promoting
psychotropic agents) [11]. Notwithstanding
the potential confounding effects of other
contributing factors, alterations in immune
inflammatory systems in adults with MDD are
also reported in individuals without
comorbidities and who are medication-naı¨ve
[14]. Moreover, the observation of alterations in
messenger RNA transcripts in unaffected
relatives of probands with mood disorders
provides further evidence that disturbances in
inflammatory system are a trait abnormality in
adults with MDD [15].
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Interleukin-6
Interleukin-6 is a pleiotropic cytokine
synthesized and released in response to
inflammatory signaling, with both pro- and
anti-inflammatory properties. As a
pro-inflammatory cytokine, IL-6 is a potent
transcriptional stimulus for the production of
acute-phase proteins [e.g., C-reactive protein
(CRP)] [16, 17], recruitment of leukocytes, and
augmentation of the production of other
pro-inflammatory chemokines [18]. IL-6 is also
reported to play a role in anti-inflammatory
processes, including the activation and
enhanced production of anti-inflammatory
molecules (e.g., macrophage type 2, IL-1
receptor antagonist) [19, 20].
The production and method of signaling of
IL-6 has been reviewed in detail elsewhere [21].
The rationale for targeting IL-6 is further
augmented by the established
interconnectedness of IL-6, as well as other
cytokine systems, in effector systems relevant to
the pathoetiology and phenomenology of
MDD. For example, it is well established that
inflammatory cytokines modulate amino acid
synthesis, release, and availability (e.g.,
glutamate), as well as playing a critical role in
cellular respiration in oxidative processes.
Moreover, cytokine systems implicated as
abnormal in MDD are in interplay with the
hypothalamic–pituitary–adrenal (HPA) axis and
are significantly modulated by circadian
rhythms, as well as gut enterotype. Taken
together, the foregoing set of effector systems
(e.g., glutamate dysregulation, oxidative stress,
glucocorticoid signaling alterations, circadian
dysrhythmicity, and gut dysbiosis) are all
implicated as pathoetiologically relevant in
MDD [22, 23].
Preclinical and clinical evidence also
indicates that IL-6 is associated with deficits in
cognitive function [23]. Moreover, it has been
well established that amongst mixed
populations with MDD, cognitive deficits are
prevalent, persistent, and are a principal
determinant of psychosocial outcome as well
as workplace disability [24, 25]. The putative
role of IL-6 in mediating cognitive function in
adults with mood disorders provides a further
rationale for conceptualizing IL-6 as a possible
convergent substrate subserving multiple
domains of psychopathology in mood
disorders.
Furthermore, several lines of evidence
highlight the robust correlation between
elevated peripheral IL-6 concentrations and
symptom severity of MDD [6, 8]. It is
additionally reported that pretreatment
peripheral IL-6 levels are predictive of
suboptimal treatment response to
conventional antidepressant therapy [7, 26].
Central [i.e., cerebrospinal fluid (CSF)] IL-6
concentration is also reported to be elevated in
clinical populations with MDD, further
suggesting that IL-6 may be a relevant
proximate mediator of disease processes in
MDD [27].
Convergent lines of evidence indicate that
both peripheral and central IL-6 levels are also
significantly elevated in adults exhibiting
self-harm (i.e., suicide attempt) [8, 28]. For
example, Lindqvist et al. [8] reported that CSF
IL-6 levels were significantly higher in
individuals with MDD (mean = 3.76 pg/mL)
and in individuals who attempted violent
suicide (mean = 5.25 pg/mL) when compared
to healthy controls (mean = 0.64 pg/mL). In a
separate study, Janelidze et al. [28] reported
significantly higher levels of peripheral IL-6 in
individuals with MDD with history of suicide
attempt when compared to individuals with
MDD without history of suicide attempt
(p = 0.048) and healthy controls (p = 0.009).
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The foregoing observations implicate a
putatively mediational role of elevated central
and peripheral IL-6 concentrations in both
affective valence and possibly cognitive
function (e.g., impulsivity).
The potent transcriptional effect of IL-6 on
CRP, a nonspecific marker of inflammatory
activation, has implications for biosignature
characterization of MDD insofar as alterations
in CRP are a highly replicated abnormality in
clinical populations [29]. Moreover, alterations
in peripheral CRP levels are associated with
treatment response outcomes with some
antidepressants [30].
Interventional research indicates that
interferon-a (IFN-a) therapy is highly
associated with the emergence and/or
amplification of depressive symptoms. Risk for
treatment-emergent depressive symptoms with
cytokine-based therapies has been highly
associated with a single nucleotide
polymorphism (SNP) at the IL-6 gene [31]. For
example, subjects with the GG/GC genotype
were reported to have developed greater
depressive symptoms compared to those with
the CC genotype at the IL-6 gene promotor
region, where the G allele is associated with
higher transcriptional activity resulting in
higher plasma IL-6 compared to the C allele.
In a separate study, peripherally
administered IFN-a was reported to activate
central nervous system (CNS) inflammatory
responses, as indicated by increased CSF IL-6
and IFN-a levels. Results of the foregoing study
indicated that the increase in CSF IL-6 levels
significantly correlated with a decrease in the
concentration of serotonin metabolite
5-hydroxyindoleacetic acid (5-HIAA) [32]. The
foregoing collection of convergent findings
implicates dysregulation of IL-6 as a critical
pathogenetic molecular substrate and possible
target in adults with MDD.
Sirukumab is a human monoclonal antibody
that targets soluble IL-6 with high affinity and
specificity [33]. Sirukumab targets the IL-6
signaling pathway, inhibiting both the pro-
and anti-inflammatory effects of the
pleiotropic cytokine IL-6. Interventional
studies with sirukumab have been conducted
across a variety of inflammatory disorders,
including cutaneous or systemic lupus
erythematosus (CLE/SLE) and rheumatoid
arthritis (RA) [33–38]. Results from studies
with sirukumab in clinical populations with
inflammatory disorders provide evidence of
beneficial effects on patient-reported outcomes
(PROs), including measures of global
functioning and quality of life. Herein, we
review studies from both preclinical and
clinical research that provide an empirical
basis for hypothesizing that sirukumab is a
possible symptom-mitigating and
disease-modifying treatment. The application
of sirukumab to MDD is chosen as an exemplar
of its brain-based potential application, with
recognition that there could be applications
transdiagnostically in psychiatry.
METHODS
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors. The PubMed/Medline database was
searched from inception to September 16, 2016
using combinations of the following search
terms: sirukumab; anti-IL-6; IL-6; major
depressive disorder; inflammation. Included
articles were clinical trials reporting on the
pharmacology of sirukumab, as well as
preclinical studies investigating the efficacy of
targeting IL-6 signaling in murine models of
depression. Article reference lists were also
reviewed for additional articles aligned with
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the overarching aim of this paper. Altogether,
11 preclinical and clinical trials were included
in this review. Studies included for this review
were those that reported specifically on
preclinical and clinical models of depression,
cognition, and/or evaluated the effects of
sirukumab/IL-6 on neurobiological systems
relevant to the pathoetiology of depression.
We also sought present clinical trials on
clinicaltrials.gov by entering the search words
‘‘sirukumab, psychiatry, depression, cognition’’.
RESULTS
Pharmacokinetics
Interventional clinical studies with sirukumab
in healthy subjects as well as clinical
populations with CLE, SLE, or RA have
reported a biphasic pharmacokinetic profile,
specifically a relatively quick distribution
phase followed by a relatively slow elimination
phase [33, 35]. The slow elimination phase of
sirukumab is consistent with its relatively long
half-life. In a study evaluating the effects of
sirukumab in healthy human subjects,
sirukumab was reported to have a median
half-life of 18.5–29.6 days following 10–15 min
intravenous (IV) infusions of 0.3-10 mg/kg
doses [33]. The mean half-life of sirukumab
following subcutaneous (SC) administration of
sirukumab for healthy subjects is reportedly
shorter than the mean half-life following IV
administration (i.e., 15–18 vs. 19–30 days,
respectively) [36].
The average maximum serum concentration
(Cmax) value has been reported to increase in a
dose-dependent manner in healthy subjects
(i.e., 7.9–248.8 lg/mL for doses of 0.3–10 mg/
kg). Similarly, the area under the serum
concentration–time curve (AUC) values (i.e.,
drug absorption values) were reported to
increase in a dose-dependent manner
(r2 = 0.996 and r2 = 0.973 for AUC and Cmax,
respectively) [33]. The clearance rate of the
drug was reported to be independent of dosage
in healthy subjects (mean 3.8–6.1
mg day-1 kg-1). Interestingly, all
pharmacokinetic parameters (e.g., Cmax, AUC,
clearance) have been consistent across mixed
populations, independent of gender and race
[33, 36].
Pharmacodynamics
Replicated evidence suggests that sirukumab
administration decreases peripheral CRP levels
in healthy subjects [33, 34]. In healthy subjects,
a decrease of at least 50% from baseline CRP
levels was observed for all dosages ranging from
0.3 to 10 mg/kg [33]. Efficacy of sirukumab in
CRP reduction was further evidenced in studies
of patients with inflammatory disorders.
Smolen et al. [34] reported significant
decreases in CRP levels with 100-mg biweekly
administrations of sirukumab compared to
placebo in subjects with RA (-91% vs. -20%,
respectively). Suppression of peripheral CRP
levels was evident within 2 weeks of
sirukumab administration and was sustained
for 24 weeks [34].
Szepietowski et al. [35] reported a significant
decrease in mean peripheral CRP levels from
1 week following sirukumab treatment and
remained suppressed for up to 14 weeks in
subjects with CLE or SLE. The suppression of
peripheral CRP levels associated with sirukumab
treatment persists beyond the elimination
half-life of sirukumab in subjects with CLE,
SLE, or RA. Peripheral CRP suppression
appeared to be dose-independent in all studies
[33–35].
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Preclinical Evidence
Convergent evidence from murine models
suggests that inhibition of IL-6 signaling may
offer protection against incident depression-like
behavior. For example, Chourbaji et al. [37]
reported a significant association between IL-6
and depressive behavior. IL-6 knockout (KO)
mice were more resilient and less likely to
exhibit despair than IL-6 wild-type (WT) mice
in stress paradigms (i.e., forced swim, tail
suspension, foot shock) [37]. In addition, WT
mice exhibited an increase in hippocampal IL-6
expression compared to KO mice. Furthermore,
KO mice exhibited enhanced hedonic behavior,
as measured by sensitivity to rewards (i.e.,
sucrose), compared to WT mice.
Similarly, a separate line of evidence
reported a significant association between
elevated levels of endogenous cortical IL-6
expression and depression-like phenotypes
(e.g., immobility time on tail suspension,
forced swim tests). Fluoxetine does not
mitigate the onset of depression-like
symptoms in mice with endogenously elevated
levels of IL-6 in the CNS or in mice exogenously
administered IL-6 into the CSF [38]. It should be
noted, however, that the administration of an
anti-IL-6 antibody was able to alleviate
depression-like symptoms following CSF IL-6
administration [38].
Moreover, Hodes et al. [39] reported that
preexisting individual differences in the
peripheral immune system could predict
emotional response to social stressors, as
illustrated by murine response to repeated
social defeat stress (RSDS) paradigms. Results
showed that mice susceptible to stress had
significantly higher serum IL-6 within 20 min
of treatment. IL-6 elevation effects were
persistent following subsequent chronic stress
(i.e., IL-6 levels remained elevated for over
1 month after exposure). Mice that underwent
emotional stress (i.e., witness defeat) also had
significantly elevated serum IL-6 levels relative
to controls [39]. Emotional response (i.e.,
resilience versus vulnerability) to social stress
was demonstrated to be controlled via
alterations of periphery IL-6 levels [39]. IL-6-/-
mice and IL-6-/- bone marrow (BM) chimeras
exhibited resilience, as measured by levels of
social interaction following RSDS. By contrast,
BM chimeras from high-IL-6-releasing controls
exhibited social avoidance behavior. Hodes
et al. [39] also reported that the injection of
IL-6 monoclonal antibodies in mice was able to
successfully block the development of social
avoidance.
Clinical Evidence
Available evidence indicates that conventional
monoamine-based antidepressants exert
indirect effects on the innate immune system
[40]. It is also reported that baseline
inflammatory markers/signature may have
moderate effects on response outcomes in
adults with MDD [41]. Interventional trials
evaluating conventional antidepressants are
limited by significant heterogeneity in sample
composition, types of anti-inflammatory agents
employed, dependent measures, and response
outcome [42]. The notion that a subset of adults
with MDD stratified on the basis of an elevated
inflammatory marker may be differentially
responsive to anti-inflammatory intervention
is supported by results of a recently published
study [43]. The post hoc finding by Raison et al.
[43] reported that subjects with baseline serum
high-sensitivity (hs) CRP levels greater than
5 mg/L were significantly more likely to
respond to the tumor necrosis factor (TNF)
antagonist infliximab [43], whereas subjects
with baseline hs-CRP levels no greater than
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5 mg/L were more likely to respond to placebo.
The foregoing study result, in need of
replication, provides empirical evidence that a
specific anti-inflammatory biologic is
differentially effective in a subset of adults
with MDD stratified by phenomenological and
biological characteristics.
Patient-Reported Outcomes
Sirukumab has been demonstrated to rapidly
reduce peripheral CRP levels in clinical
populations with inflammatory disorders as
well as in healthy populations. Results from
clinical trials in patient populations with CLE,
SLE, or RA suggest that inhibiting IL-6 may
improve patient-reported outcomes in
individuals with inflammatory disorders. For
example, a phase I, randomized, double-blind,
placebo-controlled study investigated the
efficacy of sirukumab in 36 subjects with CLE
or SLE [35]. As a secondary outcome,
Szepietowski et al. [35] assessed functional and
mental health outcomes using the Short Form
36 (SF-36) Mental Component Summary (MCS),
a self-administered assessment of social
functioning, vitality, emotional well-being,
and emotional role impairment. In subjects
with CLE, sirukumab significantly improved
median SF-36 MCS scores (?2.0) at week 22,
whereas placebo worsened median scores
(-4.0). In subjects with SLE, median SF-36
MCS scores improved at week 10 (?3.9 with
sirukumab vs. -4.2 with placebo), although
improvements were not significant at week 22
(?0.45 with sirukumab vs. ?0.7 with placebo)
16 weeks after the last study infusion [35].
A separate line of evidence also reported
functional improvements in a patient
population with RA in response to sirukumab
treatment. In part A of a two-part, phase II,
randomized, placebo-controlled study, Smolen
et al. [34] reported significant improvements
with sirukumab compared to placebo (0.74 vs.
0.17, p\0.001) (i.e., change from baseline to
endpoint) on the Health Assessment
Questionnaire Disability Index (HAQ-DI) in 36
subjects with RA. The HAQ-DI is a measure of
disability-related functional outcomes that
includes measures of mental health (e.g.,
dressing and grooming). In the larger,
dose-finding part B of the foregoing clinical
trial, Smolen et al. reported improvements in
HAQ-DI with variable doses of sirukumab in 151
subjects with RA, although the differences were
not statistically significant when compared to
placebo (0.29–0.53 vs. 0.16, respectively; p value
not reported). Improvements in quality of life,
as evidenced by change in scores on the SF-36,
were also detected in both interventional
groups (i.e., sirukumab and placebo) for part A
(6.4 vs. 3.3, respectively) and B (3.2–7.9 vs. 5.1,
respectively) [34]. The foregoing improvements
in PROs provide the basis for hypothesizing that
sirukumab may mitigate symptoms as part of a
neuropsychiatric disorder (e.g., MDD).
Safety/Tolerability
Replicated studies indicate that IV or SC
administration of sirukumab at variable doses
is safe and well tolerated [33]. The most
commonly reported adverse events (AEs) with
sirukumab treatment are headache,
pharyngolaryngeal pain, nasopharyngitis, and
mild upper respiratory tract infections [33]. A
greater proportion of placebo-treated healthy
subjects experienced one or more AEs compared
to sirukumab-treated healthy subjects (72.7%
vs. 55.9% for placebo and sirukumab,
respectively) [33]. The foregoing reports
suggest that AEs experienced by healthy
subjects following IV administration of
sirukumab are unlikely to be attributed
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directly to sirukumab. Similarly, 20 of 49
healthy subjects (61%) receiving sirukumab
subcutaneously compared to 6 of 13 healthy
subjects (46%) receiving placebo reported acute
AEs (i.e., within 2 days or less) of mild to
moderate intensity (i.e., toxicity grade 1–2)
[36]. The safety and tolerability profile of SC
sirukumab is similar to that of the IV
formulation, with headaches, upper respiratory
tract infections, and mild injection site
erythema being the most commonly reported
treatment-emergent AEs [36].
Sirukumab is also safe and well tolerated in
clinical populations of individuals with
inflammatory disorders. The incidence of AEs
was similar for sirukumab-treated and
placebo-treated subjects with RA (67.8–70.6 vs.
63.2–66.7%, respectively) [34] but greater with
sirukumab treatment compared to placebo in
subjects with CLE (21 of 23 vs. 5 of 8 subjects,
respectively) or SLE (9 of 10 vs. 4 of 5 subjects,
respectively) [35]. Mild respiratory infections
and injection site reactions were most
commonly reported in subjects with CLE, SLE,
or RA. Severe adverse events (SAE) (e.g.,
pneumonia, staphylococcal cellulitis,
fibrosarcoma) were reported by 8.8% of
sirukumab-treated subjects compared to 13.3%
of placebo-treated subjects with RA [34]. No
opportunistic infections, cases of tuberculosis,
or gastrointestinal perforations occurred in
subjects with RA in a phase II study [34].
Overall, the safety profile of sirukumab in
patients with RA was reported to be similar to
that of other IL-6 inhibitor treatments for RA
(e.g., tocilizumab, sarilumab, and
clazakizumab) [34].
Severe adverse events (e.g., pneumonia,
iatrogenic wound infection) were reported in 3
of 23 sirukumab-treated subjects with CLE, 2 of
10 sirukumab-treated subjects with SLE, and 1
of 5 placebo-treated subjects with SLE [35].
None of the aforementioned SAEs were
considered by the investigators to be related to
the study agent, except for the case of
pneumonia [35]. Furthermore, SAEs
experienced by sirukumab-treated patients
with an inflammatory disorder may be
confounded by a compromised immune
response.
The presence of antibodies to biologics (e.g.,
sirukumab) may reduce overall efficacy and/or
increase susceptibility to treatment-emergent
AEs. Antibodies to sirukumab were not
detected in healthy populations following IV
or SC administration or in populations with
CLE or SLE [33, 35, 36]. In two clinical trials,
antibodies to sirukumab were not detected in
any of 31 subjects with RA and were identified
in only 2 of 142 subjects with RA [34]. To date,
only safety results from relatively small phase II
studies are available in the public domain.
Several phase II and III studies with sirukumab
are currently underway and will soon be




A cautious interpretation of the foregoing
studies is warranted and, at best targeting IL-6
would need to be considered preliminary and
promising. At this point in time, targeting IL-6
systems would need to be conceptualized as a
promising approach, rather than an established
approach. Molecular, cellular, and
brain-circuit-based studies indicate that IL-6 as
well as other inflammatory effectors are relevant
to normal and pathological brain states. The
foregoing provides the rationale for
hypothesizing that an agent that targets IL-6
(e.g., sirukumab) may have the capability of
improving self-reported, as well as objectively
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rated, psychopathology symptoms and possibly
reversing pathological changes observed within
and between brain circuits. Notwithstanding,
proof-of-concept studies, particularly with
target engagement, along with evidence of
safety and improvement in behavioral
measures are warranted.
Sirukumab represents a possible candidate
approach insofar as it has been reported to be a
safe and well-tolerated agent that is capable of
modulating the immune response in healthy
populations and in subjects with inflammatory
disorders principally by inhibiting the IL-6
signaling pathway. Sirukumab’s tolerability
profile is similar to the reported tolerability of
other safe and well-tolerated inflammatory
agents that are also efficacious in targeting
IL-6 pathways (e.g., tocilizumab). Furthermore,
sirukumab has consistently been reported to
exhibit linear PK characteristics with a fast
distribution phase and a slow elimination
phase. In addition, sirukumab has been
reported to have a relatively long half-life of
approximately 18–30 days with IV infusion or
approximately 15–18 days with SC injection.
Convergent evidence implicates a disruption
of the inflammatory system in the pathogenesis
and/or phenomenology in a subpopulation of
adults with MDD. Furthermore, elevated levels
of pro-inflammatory cytokines (e.g., IL-6) and
acute-phase reactants (e.g., CRP) are associated
with depressive symptoms in preclinical models
as well as clinical populations of patients with
MDD. Sirukumab’s ability to improve PROs that
proxy positive mental health and well-being in
adults with inflammatory disorders provides the
basis for hypothesizing that they may be
capable of mitigating symptoms and
disease-modify illness activity amongst adults
with a diagnosable brain disorder.
The National Institute of Mental Health has
proposed the biobehavioral matrix RDoC
(Research Domain Criteria). The overarching
aim of RDoC is to identify neurobiological
substrates that subserve convergent domains
of psychopathology across psychiatry. The
RDoC has proposed five discrete domains, all
of which have subdomain ‘‘units of analysis’’.
Within the RDoC matrix, positive valence
system disturbances are referred to as
alterations in reward, response, learning, and
valuation. Negative valence disturbances refer
to threat (e.g., acute, sustained, anticipated). A
separate domain for general cognition
processes, as well as attachment/affiliation and
arousal/circadian disturbances, are
operationalized. Results from both preclinical
and clinical evidence indicate that alterations in
the innate immune inflammatory system may
be relevant at molecular, cellular, and brain
circuit levels across each of the foregoing
domains, operationalized by the RDoC. Extant
literature indicates that disturbances in the
innate immune system result in psychomotor
retardation, alterations in reward, as well as
increase in anxiety, arousal, and alarm systems
activity. A derivative of this is that a treatment
strategy targeting innate immune inflammatory
systems (e.g., sirukumab) may intentionally
have domain-specific efficacy that is
transdiagnostic (e.g., anhedonia). We would
propose that the investigation of sirukumab
would be well suited to the RDoC taxonomy
with particular interest in positive/negative
valence systems, general cognition, as well as
arousal/circadian rhythm disturbances (Fig. 1).
The foregoing hypothesis is being
empirically tested in an ongoing randomized,
placebo-controlled, double-blind phase II study
that aims to test the efficacy and safety of
sirukumab as an adjunctive treatment to
monoaminergic antidepressant therapy in
adults with MDD (NCT02473289). In addition
to mitigating conventional depression outcome
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measures (e.g., reduction in overall depression
symptom severity), the totality of evidence
would suggest that an inflammatory-based
approach may be particularly effective for the
dimension/domain of general cognitive
disturbances, as well as positive and negative
emotional valence abnormalities [23].
A strategic approach that would need to be
kept in mind when evaluating sirukumab is
replicated evidence indicating that
subpopulations of individuals with MDD may
be more likely to benefit from an intervention
that targets, directly or indirectly, the
inflammatory system. For example, evidence
indicates that individuals with higher baseline
levels of inflammatory markers would be
preferentially responsive to infliximab,
omega-3 fatty acids, exercise, and ketamine.
We would propose that the study of sirukumab
in adults with MDD should stratify patients on
the basis of elevated inflammatory markers or
signature, e.g., CRP. Moreover, sirukumab is an
expensive biologic, notwithstanding the
availability of an increasing number of
‘‘biosimilars’’. We do not envisage in the short
term that biologics will be a feasible treatment
option for most individuals with depression. At
this point, a cost-effectiveness model may
support the use of such an approach in more
tertiary treatment refractory patients; we believe
that the review herein provides a rationale for
the discovery and/or repurposing of less
expensive and scalable treatments that target
IL-6.
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